Study Protocol: A randomized, double-blind, placebo-controlled trial of isavuconazole prophylaxis for the prevention of COVID-19-associated pulmonary aspergillosis

This is the authors' abstract. We don't add key points for this paper.

During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, those with severe COVID-19 infection were at risk for a number of opportunistic infections including COVID-19-associated pulmonary aspergillosis (CAPA). We initiated a randomized clinical trial to evaluate whether isavuconazole, a triazole antifungal, could prevent CAPA and improve survival in patients admitted to the ICU with severe COVID-19 infection.